Industry: Healthcare
Published Date: June-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 210
Report ID: PMRREP34545
1. Executive Summary
1.1. US Liquid Biopsy Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 – 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. US Sectorial Outlook
2.3.2. US GDP Growth Outlook
2.3.3. US Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.4.1. List of Distribution Channel/Marketplaces
3.4.1.1. Retail
3.4.1.2. Audiology
3.4.1.3. E-Commerce
3.4.2. List of End User (Industry)
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter’s Five Force Analysis
4. US Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023–2031
4.3. US Liquid Biopsy Market Outlook: Product Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Product Type, 2018 – 2023
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
4.3.3.1. Assay Kits
4.3.3.2. Services
4.3.3.3. Instruments
4.4. Market Attractiveness Analysis: Product Type
4.5. US Liquid Biopsy Market Outlook: Biomarkers
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Biomarkers, 2018 – 2023
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
4.5.3.1. Cell-free DNA Circulating
4.5.3.2. Cell-Free RNA
4.5.3.3. Circulating Tumor Cells (CTCs)
4.5.3.4. Exosomes and Extracellular Vesicles
4.5.3.5. Others
4.6. Market Attractiveness Analysis: Biomarkers
4.7. US Liquid Biopsy Market Outlook: Application
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Mn) Analysis, By Application, 2018 – 2023
4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
4.7.3.1. Cancer Application
4.7.3.1.1. Lung Cancer
4.7.3.1.2. Breast Cancer
4.7.3.1.3. Colorectal Cancer
4.7.3.1.4. Prostate Cancer
4.7.3.1.5. Others
4.7.3.2. Non-cancer Application
4.8. Market Attractiveness Analysis: Application
4.9. US Liquid Biopsy Market Outlook: End-user
4.9.1. Introduction / Key Findings
4.9.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2018 – 2023
4.9.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
4.9.3.1. Academic and Research Institutions
4.9.3.2. Clinical Laboratories
4.9.3.3. Pharmaceutical and Biotechnology Companies
4.9.3.4. Other
4.10. Market Attractiveness Analysis: End-user
5. US Liquid Biopsy Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 – 2023
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024 – 2031
5.3.1. Northeast
5.3.2. Midwest
5.3.3. Southeast
5.3.4. Southwest
5.3.5. West
5.4. Market Attractiveness Analysis: Region
6. Northeast Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
6.3.1. By Country
6.3.2. By Product Type
6.3.3. By Biomarkers
6.3.4. By Application
6.3.5. By End-user
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
6.4.1. Assay Kits
6.4.2. Services
6.4.3. Instruments
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
6.5.1. Cell-free DNA Circulating
6.5.2. Cell-Free RNA
6.5.3. Circulating Tumor Cells (CTCs)
6.5.4. Exosomes and Extracellular Vesicles
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
6.6.1. Cancer Application
6.6.1.1. Lung Cancer
6.6.1.2. Breast Cancer
6.6.1.3. Colorectal Cancer
6.6.1.4. Prostate Cancer
6.6.1.5. Others
6.6.2. Non-cancer Application
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
6.7.1. Academic and Research Institutions
6.7.2. Clinical Laboratories
6.7.3. Pharmaceutical and Biotechnology Companies
6.7.4. Other
6.8. Market Attractiveness Analysis
7. Midwest Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
7.3.1. By Country
7.3.2. By Product Type
7.3.3. By Biomarkers
7.3.4. By Application
7.3.5. By End-user
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
7.4.1. Assay Kits
7.4.2. Services
7.4.3. Instruments
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
7.5.1. Cell-free DNA Circulating
7.5.2. Cell-Free RNA
7.5.3. Circulating Tumor Cells (CTCs)
7.5.4. Exosomes and Extracellular Vesicles
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
7.6.1. Cancer Application
7.6.1.1. Lung Cancer
7.6.1.2. Breast Cancer
7.6.1.3. Colorectal Cancer
7.6.1.4. Prostate Cancer
7.6.1.5. Others
7.6.2. Non-cancer Application
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
7.7.1. Academic and Research Institutions
7.7.2. Clinical Laboratories
7.7.3. Pharmaceutical and Biotechnology Companies
7.7.4. Other
7.8. Market Attractiveness Analysis
8. Southeast Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
8.3.1. By Country
8.3.2. By Product Type
8.3.3. By Biomarkers
8.3.4. By Application
8.3.5. By End-user
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
8.4.1. Assay Kits
8.4.2. Services
8.4.3. Instruments
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
8.5.1. Cell-free DNA Circulating
8.5.2. Cell-Free RNA
8.5.3. Circulating Tumor Cells (CTCs)
8.5.4. Exosomes and Extracellular Vesicles
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
8.6.1. Cancer Application
8.6.1.1. Lung Cancer
8.6.1.2. Breast Cancer
8.6.1.3. Colorectal Cancer
8.6.1.4. Prostate Cancer
8.6.1.5. Others
8.6.2. Non-cancer Application
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
8.7.1. Academic and Research Institutions
8.7.2. Clinical Laboratories
8.7.3. Pharmaceutical and Biotechnology Companies
8.7.4. Other
8.8. Market Attractiveness Analysis
9. Southwest Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Biomarkers
9.3.4. By Application
9.3.5. By End-user
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
9.4.1. Assay Kits
9.4.2. Services
9.4.3. Instruments
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
9.5.1. Cell-free DNA Circulating
9.5.2. Cell-Free RNA
9.5.3. Circulating Tumor Cells (CTCs)
9.5.4. Exosomes and Extracellular Vesicles
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
9.6.1. Cancer Application
9.6.1.1. Lung Cancer
9.6.1.2. Breast Cancer
9.6.1.3. Colorectal Cancer
9.6.1.4. Prostate Cancer
9.6.1.5. Others
9.6.2. Non-cancer Application
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
9.7.1. Academic and Research Institutions
9.7.2. Clinical Laboratories
9.7.3. Pharmaceutical and Biotechnology Companies
9.7.4. Other
9.8. Market Attractiveness Analysis
10. West Liquid Biopsy Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Biomarkers
10.3.4. By Application
10.3.5. By End-user
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2024 – 2031
10.4.1. Assay Kits
10.4.2. Services
10.4.3. Instruments
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarkers, 2024 – 2031
10.5.1. Cell-free DNA Circulating
10.5.2. Cell-Free RNA
10.5.3. Circulating Tumor Cells (CTCs)
10.5.4. Exosomes and Extracellular Vesicles
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 – 2031
10.6.1. Cancer Application
10.6.1.1. Lung Cancer
10.6.1.2. Breast Cancer
10.6.1.3. Colorectal Cancer
10.6.1.4. Prostate Cancer
10.6.1.5. Others
10.6.2. Non-cancer Application
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2024 – 2031
10.7.1. Academic and Research Institutions
10.7.2. Clinical Laboratories
10.7.3. Pharmaceutical and Biotechnology Companies
10.7.4. Other
10.8. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2023
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
11.3.1. Biocept, Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Products
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Qiagen N.V.
11.3.2.1. Overview
11.3.2.2. Segments and Products
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Illumina, Inc.
11.3.3.1. Overview
11.3.3.2. Segments and Products
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Myriad Genetics, Inc.
11.3.4.1. Overview
11.3.4.2. Segments and Products
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Thermo Fisher Scientific, Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Products
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Guardant Health
11.3.6.1. Overview
11.3.6.2. Segments and Products
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. F. Hoffmann-La Roche Ltd
11.3.7.1. Overview
11.3.7.2. Segments and Products
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. ANGLE plc.
11.3.8.1. Overview
11.3.8.2. Segments and Products
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. BIODESIX
11.3.9.1. Overview
11.3.9.2. Segments and Products
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. NeoGenomics Laboratories, Inc.
11.3.10.1. Overview
11.3.10.2. Segments and Products
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
